Literature DB >> 9551768

Effects of AMPA receptor antagonists on dopamine-mediated behaviors in mice.

K E Vanover1.   

Abstract

Current data indicate that dopaminergic and glutamatergic neurotransmitter systems interact. The role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) glutamate receptor subtypes in modulating dopamine neurotransmission, however, remains unclear. The noncompetitive AMPA antagonists, GYKI 52466 (5-40 mg/kg) and LY300164 (1-6 mg/kg), and the competitive AMPA antagonists, LY326325 (5-80 mg/kg) and NBQX (10-80 mg/kg), were compared to the dopamine antagonist, haloperidol (0.03-1.0 mg/kg), for their ability to inhibit dopamine-mediated behaviors after i.p. administration in mice. The behavioral paradigms included amphetamine- or dizocilpine-induced hyperactivity, amphetamine-induced stereotyped sniffing, and apomorphine-induced climbing and stereotyped sniffing. All four AMPA antagonists and haloperidol attenuated amphetamine- and dizocilpine-induced hyperactivity and decreased spontaneous locomotion. Haloperidol and GYKI 52466 were more potent against amphetamine than against dizocilpine. In contrast, LY326325 was more potent against dizocilpine than against amphetamine. The hyperactivity decreases by LY300164 and NBQX were most likely due to non-specific effects on motor behavior. The AMPA antagonists and haloperidol also attenuated amphetamine- induced stereotypy. Unlike haloperidol, however, GYKI 52466, LY300164, and NBQX failed to attenuate apomorphine-induced climbing and stereotyped sniffing. LY326325, on the other hand, attenuated apomorphine-induced stereotypy, but not climbing. These results indicate that AMPA receptor antagonists can attenuate the behavioral effects of drugs, such as amphetamine and dizocilpine, that increase dopamine neurotransmission. However, the behavioral effects of the direct dopamine agonist apomorphine are not consistently attenuated by AMPA antagonists. The competitive AMPA receptor antagonist LY326325 appears to have a profile distinct from both haloperidol and the other AMPA antagonists tested.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9551768     DOI: 10.1007/s002130050547

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  7 in total

1.  No good deed goes unpunished!

Authors:  Alfred Ayala; Doreen E Wesche-Soldato; Megan Garber; Ryan Swan; Mario Perl
Journal:  Intensive Care Med       Date:  2006-04-01       Impact factor: 17.440

2.  Effects of selective calcium-permeable AMPA receptor blockade by IEM 1460 on psychotomimetic-induced hyperactivity in the mouse.

Authors:  Masakazu Umino; Asami Umino; Toru Nishikawa
Journal:  J Neural Transm (Vienna)       Date:  2017-12-21       Impact factor: 3.575

3.  Nicotine-induced dopamine release in the nucleus accumbens is inhibited by the novel AMPA antagonist ZK200775 and the NMDA antagonist CGP39551.

Authors:  Alexander R Kosowski; Gvido Cebers; Aleta Cebere; Ann-Charlott Swanhagen; Sture Liljequist
Journal:  Psychopharmacology (Berl)       Date:  2004-04-16       Impact factor: 4.530

4.  Does gene deletion of AMPA GluA1 phenocopy features of schizoaffective disorder?

Authors:  Paul J Fitzgerald; Chris Barkus; Michael Feyder; Lisa M Wiedholz; Yi-Chyan Chen; Rose-Marie Karlsson; Rodrigo Machado-Vieira; Carolyn Graybeal; Trevor Sharp; Carlos Zarate; Judith Harvey-White; Jing Du; Rolf Sprengel; Peter Gass; David Bannerman; Andrew Holmes
Journal:  Neurobiol Dis       Date:  2010-08-08       Impact factor: 5.996

5.  In vitro and in vivo studies in rats with LY293558 suggest AMPA/kainate receptor blockade as a novel potential mechanism for the therapeutic treatment of anxiety disorders.

Authors:  Andrew Alt; Brianne Weiss; Ann Marie Ogden; Xia Li; Scott D Gleason; David O Calligaro; David Bleakman; Jeffrey M Witkin
Journal:  Psychopharmacology (Berl)       Date:  2006-02-10       Impact factor: 4.530

6.  A role of ADAR2 and RNA editing of glutamate receptors in mood disorders and schizophrenia.

Authors:  Mie Kubota-Sakashita; Kazuya Iwamoto; Miki Bundo; Tadafumi Kato
Journal:  Mol Brain       Date:  2014-01-21       Impact factor: 4.041

Review 7.  Animal models for bipolar disorder: from bedside to the cage.

Authors:  Dominik K E Beyer; Nadja Freund
Journal:  Int J Bipolar Disord       Date:  2017-10-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.